Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke

Metformin is currently the first‐line treatment drug for type 2 diabetes. Metformin is a well‐known activator of AMP‐activated protein kinase (AMPK). In experimental studies, metformin has been shown to exert direct vascular effects by increasing vascular endothelial growth factor expression and imp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European journal of neuroscience 2014-06, Vol.39 (12), p.2129-2138
Hauptverfasser:	Venna, Venugopal R., Li, Jun, Hammond, Matthew D., Mancini, Nickolas S., McCullough, Louise D.
Format:	Artikel
Sprache:	eng
Schlagworte:	AMP-Activated Protein Kinases - genetics AMP-Activated Protein Kinases - metabolism AMPK Animals apomorphine Apomorphine - pharmacology Brain - drug effects Brain - pathology Brain - physiopathology cerebral ischemia Disease Models, Animal Dopamine Agonists - pharmacology Infarction, Middle Cerebral Artery - drug therapy Infarction, Middle Cerebral Artery - pathology Infarction, Middle Cerebral Artery - physiopathology Male metformin Metformin - pharmacology Mice, Inbred C57BL Mice, Knockout Motor Activity - drug effects Motor Activity - physiology Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - pathology Neovascularization, Pathologic - physiopathology Neuroglia - drug effects Neuroglia - physiology Neuroprotective Agents - pharmacology Physical Stimulation Random Allocation Recovery of Function - drug effects Recovery of Function - physiology Stroke Vascular Endothelial Growth Factor A - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!